Sailun Pharma's wholly-owned subsidiary has obtained a drug registration certificate for Aspartate Potassium Magnesium Injection from the NMPA. This product is mainly used for treating hypokalemia and as an auxiliary treatment for ventricular arrhythmias caused by digitalis poisoning, sequelae of myocarditis, congestive heart failure, and myocardial infarction. The approval enriches the company's product portfolio.
Summary generated by AI · Always verify with source document
Securities Code: 002898 Securities Abbreviation: *ST Sailun Announcement No.: 2026-067
Sailun Pharma Group Co., Ltd. Announcement on Subsidiary Obtaining Drug Registration Certificate for Aspartate Potassium Magnesium Injection
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.